Clinigen Group opens Global Operations Centre
Will improve distribution and stock levels
Peter George, chief executive of Clinigen, said: ‘We are continuing to expand and have ambitious plans for the future. It is essential that we have the right resource and facilities to service our clients, both now, and as we continue to develop.’
The firm says the new 8,000ft2 warehousing and distribution facilities will enable it to stock and distribute pharmaceutical products to its global customer base in a fast and efficient manner.
The new Operations Centre combined with the company's headquarters in Burton, have created more than 30 new jobs in recent months. In total the firm employs 300 staff.
Clinigen Group was formed in 2010 by the merger of three companies: Clinigen CTS (formerly Keats Healthcare) and Clinigen GAP, which make up Clinigen's services division, and Clinigen Healthcare, the Group's products business.
The Group operates across the clinical lifecycle of a drug, from Phase 1 clinical trials to the end of patent and beyond.
You may also like
Distribution
Santhera and Clinigen partner to distribute DMD treatment AGAMREE to eligible patients globally
Read moreClinigen Group will be respsonsible for the distribution of Duchenne muscular dystrophy (DMD) treatment AGAMREE (vamorolone) in regions not currently covered by Santhera or its distribution partners
Trending Articles
You may also like
Distribution
Santhera and Clinigen partner to distribute DMD treatment AGAMREE to eligible patients globally
Clinigen Group will be respsonsible for the distribution of Duchenne muscular dystrophy (DMD) treatment AGAMREE (vamorolone) in regions not currently covered by Santhera or its distribution partners
Pharmaceutical
CPHI Frankfurt 2025 to welcome more than 60,000 pharma professionals with expanded focus on innovation and sustainability
Returning to Germany from 28-30 October, CPHI Frankfurt 2025 will unite the global pharmaceutical supply chain with more than 2000 exhibitors, six content theatres and new feature zones
Manufacturing
Continuous innovation: redefining the future of pharmaceutical manufacturing
In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced